PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
Explore related content and topics
White Paper
PBRERs – Pitfalls and Misconceptions
Following the release of ICH guideline E2C (R2) Step 5 on the Periodic Benefit-Risk Evaluation Report (PBRER) in January 2013 and EU GVP Module VII –…
Fact Sheet
Risk Management Services
PRA Health Sciences (PRA) experts have significant experience providing end-to-end risk management services. Our integrated global teams identify…
Fact Sheet
Literature Surveillance: Important Information About Patient Safety
Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their…